Towards Understanding the Roles of Heparan Sulfate Proteoglycans in Alzheimer's Disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Zhang, Gan Lin ^a   Zhang, Xiao ^b   Wang, Xiao Min ^a   Li, Jin Ping ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; HEPARAN SULFATE; HEPARANASE; PROTEOHEPARAN SULFATE; BETA GLUCURONIDASE;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; CYTOTOXICITY; ENZYME STRUCTURE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; ANIMAL; BRAIN; CELL MOTION; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALIA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CELL MOVEMENT; GLUCURONIDASE; HEPARAN SULFATE PROTEOGLYCANS; HUMANS;

EID: 84935917108     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/516028     Document Type: Review

References (103)

1. S. Sarrazin, W. C. Lamanna, and J. D. Esko, "Heparan sulfate proteoglycans, " Cold Spring Harbor Perspectives in Biology, vol. 3, no. 7, 2011.
2. J. Kreuger and L. Kjellen, "Heparan sulfate biosynthesis: regulation and variability, " Journal of Histochemistry and Cytochemistry, vol. 60, no. 12, pp. 898-907, 2012.
3. U. Lindahl and J. Li, "Interactions between heparan sulfate and proteins-design and functional implications, " International Review of Cell and Molecular Biology, vol. 276, pp. 105-159, 2009.
4. J. R. Bishop, M. Schuksz, and J. D. Esko, "Heparan sulphate proteoglycans fine-tune mammalian physiology, " Nature, vol. 446, no. 7139, pp. 1030-1037, 2007.
5. A. Yayon, M. Klagsbrun, J. D. Esko, P. Leder, and D. M. Ornitz, "Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor, " Cell, vol. 64, no. 4, pp. 841-848, 1991.
6. L. Karlsson-Lindahl, L. Schmidt, D. Haage, et al., "Heparanase affects food intake and regulates energy balance in mice, " PLoS ONE, vol. 7, no. 3, Article ID e34313, 2012.
7. O. Reizes, S. C. Benoit, A. D. Strader, D. J. Clegg, S. Akunuru, and R. J. Seeley, "Syndecan-3modulates food intake by interacting with the melanocortin/AgRP pathway, " Annals of the New York Academy of Sciences, vol. 994, pp. 66-73, 2003.
8. A. D. Strader, O. Reizes, S. C. Woods, S. C. Benoit, and R. J. Seeley, "Mice lacking the syndecan-3 gene are resistant to dietinduced obesity, " Journal of Clinical Investigation, vol. 114, no. 9, pp. 1354-1360, 2004.
9. H. C. Christianson and M. Belting, "Heparan sulfate proteoglycan as a cell-surface endocytosis receptor, " Matrix Biology, vol. 35, pp. 51-55, 2014.
10. G. Tsen, W. Halfter, S. Kroger, and G. J. Cole, "Agrin is a heparan sulfate proteoglycan, "The Journal of Biological Chemistry, vol. 270, no. 7, pp. 3392-3399, 1995.
11. A. D. Murdoch, G. R. Dodge, I. Cohen, R. S. Tuan, and R. V. Iozzo, "Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor, " Journal of Biological Chemistry, vol. 267, no. 12, pp. 8544-8557, 1992.
12. R. Kalluri, "Basement membranes: structure, assembly and role in tumour angiogenesis, " Nature Reviews Cancer, vol. 3, no. 6, pp. 422-433, 2003.
13. H. J. Guretzki, E. Schleicher, K. D. Gerbitz, and B. Olgemoller, "Heparin induces endothelial extracellular matrix alterations and barrier dysfunction, " American Journal of Physiology, vol. 267, no. 4, part 1, pp. C946-C954, 1994.
14. M. Costell, E. Gustafsson, A. Aszodi, et al., "Perlecan maintains the integrity of cartilage and some basement membranes, " Journal of Cell Biology, vol. 147, no. 5, pp. 1109-1122, 1999.
15. A. Asplund, G. Ostergren-Lunden, G. Camejo, P. Stillemark-Billton, and G. Bondjers, "Hypoxia increases macrophage motility, possibly by decreasing the heparan sulfate proteoglycan biosynthesis, " Journal of Leukocyte Biology, vol. 86, no. 2, pp. 381-388, 2009.
16. J. J. Moon, M. Matsumoto, S. Patel, L. Lee, J. Guan, and S. Li, "Role of cell surface heparan sulfate proteoglycans in endothelial cell migration and mechanotransduction, " Journal of Cellular Physiology, vol. 203, no. 1, pp. 166-176, 2005.
17. S. Floris, J. van den Born, S. M. A. van der Pol, C. D. Dijkstra, and H. E. de Vries, "Heparan sulfate proteoglycans modulate monocyte migration across cerebral endothelium, " Journal of Neuropathology and Experimental Neurology, vol. 62, no. 7, pp. 780-790, 2003.
18. P. D. Yurchenco and J. C. Schittny, "Molecular architecture of basement membranes, " The FASEB Journal, vol. 4, no. 6, pp. 1577-1590, 1990.
19. M. Paulsson, "Basement membrane proteins: structure, assembly, and cellular interactions, " Critical Reviews in Biochemistry and Molecular Biology, vol. 27, no. 1-2, pp. 93-127, 1992.
20. E. Farkas and P. G. M. Luiten, "Cerebral microvascular pathology in aging and Alzheimers disease, " Progress in Neurobiology, vol. 64, no. 6, pp. 575-611, 2001.
21. C. A. Hawkes, M. Gatherer, M. M. Sharp, et al., "Regional differences in themorphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-β from the mouse brain, " Aging Cell, vol. 12, no. 2, pp. 224-236, 2013.
22. D. S. Pikas, J. Li, I. Vlodavsky, and U. Lindahl, "Substrate specificity of heparanases fromhuman hepatoma and platelets, " Journal of Biological Chemistry, vol. 273, no. 30, pp. 18770-18777, 1998.
23. E. Zcharia, S. Metzger, T. Chajek-Shaul, et al., "Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior, " The FASEB Journal, vol. 18, no. 2, pp. 252-263, 2004.
24. E. Zcharia, J. Jia, X. Zhang, et al., "Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases, " PLoS ONE, vol. 4, no. 4, Article ID e5181, 2009.
25. M. L. Escobar Galvis, J. Jia, X. Zhang, et al., "Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate, " Nature Chemical Biology, vol. 3, no. 12, pp. 773-778, 2007.
26. A. B. Baker, W. J. Gibson, V. B. Kolachalama, et al., "Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance, " Journal of the American College of Cardiology, vol. 59, no. 17, pp. 1551-1560, 2012.
27. J. Li, M. L. EscobarGalvis, F. Gong, et al., "In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein a amyloidosis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 18, pp. 6473-6477, 2005.
28. S. Massena, G. ChristOffersson, E. Hjertstrom, et al., "Achemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils, " Blood, vol. 116, no. 11, pp. 1924-1931, 2010.
29. X. Zhang, B. Wang, P. OCallaghan, et al., "Heparanase overexpression impairs inflammatory response and macrophagemediated clearance of amyloid-β in murine brain, " Acta Neuropathologica, vol. 124, no. 4, pp. 465-478, 2012.
30. N. Ilan, M. Elkin, and I. Vlodavsky, "Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis, " International Journal of Biochemistry and Cell Biology, vol. 38, no. 12, pp. 2018-2039, 2006.
31. X. Hong, K. K. Nelson, A. C. deCarvalho, and S. N. Kalkanis, "Heparanase expression of glioma in human and animal models: laboratory investigation, " Journal of Neurosurgery, vol. 113, no. 2, pp. 261-269, 2010.
32. J. Li, X. Zhang, Z. Lu, S. P. Yu, and L. Wei, "Expression of heparanase in vascular cells and astrocytes of the mouse brain after focal cerebral ischemia, " Brain Research, vol. 1433, pp. 137-144, 2012.
33. H. Takahashi, H. Matsumoto, Y. Kumon, et al., "Expression of heparanase in nestin-positive reactive astrocytes in ischemic lesions of rat brain after transient middle cerebral artery occlusion, " Neuroscience Letters, vol. 417, no. 3, pp. 250-254, 2007.
34. I. Vlodavsky, P. Beckhove, I. Lerner, et al., "Significance of heparanase in cancer and inflammation, " CancerMicroenvironment, vol. 5, no. 2, pp. 115-132, 2012.
35. A. Riaz, N. Ilan, I. Vlodavsky, J. Li, and S. Johansson, "Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence, " The Journal of Biological Chemistry, vol. 288, no. 17, pp. 12366-12375, 2013.
36. J. Hardy and D. J. Selkoe, "The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics, " Science, vol. 297, no. 5580, pp. 353-356, 2002.
37. H. Cai, Y. Wang, D. McCarthy, et al., "BACE1 is the major β-secretase for generation of Aβ peptides by neurons, " Nature Neuroscience, vol. 4, no. 3, pp. 233-234, 2001.
38. B. A. Bergmans and B. de Strooper, " γ-secretases: from cell biology to therapeutic strategies, " The Lancet Neurology, vol. 9, no. 2, pp. 215-226, 2010.
39. J. A. Hardy and G. A. Higgins, "Alzheimers disease: the amyloid cascade hypothesis, " Science, vol. 256, no. 5054, pp. 184-185, 1992.
40. J. C. Janssen, J. A. Beck, T. A. Campbell, et al., "Early onset familial Alzheimers disease:mutation frequency in 31 families, " Neurology, vol. 60, no. 2, pp. 235-239, 2003.
41. G. Raux, L. Guyant-Marechal, C. Martin, et al., "Molecular diagnosis of autosomal dominant early onsetAlzheimers disease: an update, " Journal of Medical Genetics, vol. 42, no. 10, pp. 793-795, 2005.
42. D. Campion, C. Dumanchin, D. Hannequin, et al., "Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum, " American Journal of Human Genetics, vol. 65, no. 3, pp. 664-670, 1999.
43. C. Haass, A. Y. Hung, D. J. Selkoe, and D. B. Teplow, "Mutations associated with a locus for familial Alzheimers disease result in alternative processing of amyloid β-protein precursor, " Journal of Biological Chemistry, vol. 269, no. 26, pp. 17741-17748, 1994.
44. M. Citron, T. Oltersdorf, C. Haass, et al., "Mutation of the β-amyloid precursor protein in familial Alzheimers disease increases β-protein production, " Nature, vol. 360, no. 6405, pp. 672-674, 1992.
45. X.-D. Cai, T. E. Golde, and S. G. Younkin, "Release of excess amyloid β protein fromamutant amyloid β protein precursor, " Science, vol. 259, no. 5094, pp. 514-516, 1993.
46. K. G. Mawuenyega, W. Sigurdson, V. Ovod, et al., "Decreased clearance of CNS β-amyloid in Alzheimers disease, " Science, vol. 330, no. 6012, p. 1774, 2010.
47. R. E. Tanzi, R. D. Moir, and S. L. Wagner, "Clearance of Alzheimers Aβ peptide: the many roads to perdition, " Neuron, vol. 43, no. 5, pp. 605-608, 2004.
48. R. O. Weller, A. Massey, T. A. Newman, M. Hutchings, Y. Kuo, and A. E. Roher, "Cerebral amyloid angiopathy: amyloid β accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease, "American Journal of Pathology, vol. 153, no. 3, pp. 725-733, 1998.
49. J. S. Miners, S. Baig, J. Palmer, L. E. Palmer, P. G. Kehoe, and S. Love, "Aβ-degrading enzymes in Alzheimers disease, " Brain Pathology, vol. 18, no. 2, pp. 240-252, 2008.
50. R. Deane, R. D. Bell, A. Sagare, and B. V. Zlokovic, "Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimers disease, " CNS and Neurological Disorders, Drug Targets, vol. 8, no. 1, pp. 16-30, 2009.
51. D. Gate, K. Rezai-Zadeh, D. Jodry, A. Rentsendorj, and T. Town, "Macrophages inAlzheimers disease: the blood-borne identity, " Journal of Neural Transmission, vol. 117, no. 8, pp. 961-970, 2010.
52. R. O. Weller, M. Subash, S. D. Preston, I. Mazanti, and R. O. Carare, "Perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimers disease, " Brain Pathology, vol. 18, no. 2, pp. 253-266, 2008.
53. K. J. Bame, J. Dand a, A. Hassall, and S. Tumova, "Aβ(1-40) prevents heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover in Alzheimers disease, " Journal of Biological Chemistry, vol. 272, no. 27, pp. 17005-17011, 1997.
54. L. Buee, W. Ding, J. P. Anderson, et al., "Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide, " Brain Research, vol. 627, no. 2, pp. 199-204, 1993.
55. B. Leveugle, A. Scanameo, W. Ding, and H. Fillit, "Binding of heparan sulfate glycosaminoglycan to β-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds, " NeuroReport, vol. 5, no. 11, pp. 1389-1392, 1994.
56. D. J. Watson, A. D. Lander, and D. J. Selkoe, "Heparin-binding properties of the amyloidogenic peptides Aβ and amylin: dependence on aggregation state and inhibition by Congo red, " The Journal of Biological Chemistry, vol. 272, no. 50, pp. 31617-31624, 1997.
57. D. Giulian, L. J. Haverkamp, J. Yu, et al., "The HHQK domain of β-amyloid provides a structural basis for the immunopathology of Alzheimers disease, " The Journal of Biological Chemistry, vol. 273, no. 45, pp. 29719-29726, 1998.
58. B. Lindahl, C. Westling, G. Gimenez-Gallego, U. Lindahl, and M. Salmivirta, "Common binding sites for β-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex, " Journal of Biological Chemistry, vol. 274, no. 43, pp. 30631-30635, 1999.
59. R. Gupta-Bansal, R. C. Frederickson, and K. R. Brunden, "Proteoglycan-mediated inhibition of Aβ proteolysis: a potential cause of senile plaque accumulation, " The Journal of Biological Chemistry, vol. 270, no. 31, pp. 18666-18671, 1995.
60. A. D. Snow, J. Willmer, and R. Kisilevsky, "Sulfated glycosaminoglycans: a common constituent of all amyloids?" Laboratory Investigation, vol. 56, no. 1, pp. 120-123, 1987.
61. L. S. Perlmutter, H. C. Chui, D. Saperia, and J. Athanikar, "Microangiography and the colocalization of heparan sulfate proteoglycan with amyloid in senile plaques of Alzheimers disease, " Brain Research, vol. 508, no. 1, pp. 13-19, 1990.
62. A. D. Snow, H. Mar, D. Nochlin, et al., "The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimers disease, " American Journal of Pathology, vol. 133, no. 3, pp. 456-463, 1988.
63. J. H. Su, B. J. Cummings, and C. W. Cotman, "Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimers disease, " Neuroscience, vol. 51, no. 4, pp. 801-813, 1992.
64. J. E. Donahue, T. M. Berzin, M. S. Rafii, et al., "Agrin in Alzheimers disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 11, pp. 6468-6472, 1999.
65. J. van Horssen, J. Kleinnijenhuis, C. N. Maass, et al., "Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques, " Neurobiology of Aging, vol. 23, no. 4, pp. 537-545, 2002.
66. S. Kurup, T. J. M. Wijnhoven, G. J. Jenniskens, et al., "Characterization of anti-heparan sulfate phage display antibodies AO4B08 and HS4E4, "The Journal of Biological Chemistry, vol. 282, no. 29, pp. 21032-21042, 2007.
67. T. H. van Kuppevelt, M. A. Dennisseni, W. J. van Venrooij, R. M. A. Hoet, and J. H. Veerkamp, "Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology: further evidence for heparan sulfate heterogeneity in the kidney, "The Journal of Biological Chemistry, vol. 273, no. 21, pp. 12960-12966, 1998.
68. I. B. Bruinsma, L. te Riet, T. Gevers, et al., "Sulfation of heparan sulfate associated with amyloid-β plaques in patients with Alzheimers disease, " Acta Neuropathologica, vol. 119, no. 2, pp. 211-220, 2010.
69. G. B. T. Dam, S. Kurup, E. M. A. Van De Westerlo, et al., "3-O-sulfated oligosaccharide structures are recognized by antiheparan sulfate antibody HS4C3, " The Journal of Biological Chemistry, vol. 281, no. 8, pp. 4654-4662, 2006.
70. P. O'Callaghan, E. Sandwall, J. Li, et al., "Heparan sulfate accumulation with Aβ deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells, " Brain Pathology, vol. 18, no. 4, pp. 548-561, 2008.
71. M. A. B. A. Dennissen, G. J. Jenniskens, M. Pieffers, et al., "Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies, " The Journal of Biological Chemistry, vol. 277, no. 13, pp. 10982-10986, 2002.
72. T. Hosono-Fukao, S. Ohtake-Niimi, H. Hoshino, et al., "Heparan sulfate subdomains that are degraded by sulf accumulate in cerebral amyloid ß plaques of alzheimers disease: evidence from mouse models and patients, " The American Journal of Pathology, vol. 180, no. 5, pp. 2056-2067, 2012.
73. F. M. LaFerla, K. N. Green, and S. Oddo, "Intracellular amyloid-β in Alzheimers disease, " Nature Reviews Neuroscience, vol. 8, no. 7, pp. 499-509, 2007.
74. K. K. Kandimalla, O. G. Scott, S. Fulzele, M. W. Davidson, and J. F. Poduslo, "Mechanism of neuronal versus endothelial cell uptake of Alzheimers disease amyloid β protein, " PLoS ONE, vol. 4, no. 2, Article ID e4627, 2009.
75. T. Kanekiyo, C. Liu, M. Shinohara, J. Li, and G. Bu, "LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimers amyloid-β, " Journal of Neuroscience, vol. 32, no. 46, pp. 16458-16465, 2012.
76. D. M. Paresce, R. N. Ghosh, and F. R. Maxfield, "Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor, " Neuron, vol. 17, no. 3, pp. 553-565, 1996.
77. H. M. Nielsen, S. D. Mulder, J. A. M. Belien, R. J. P. Musters, P. Eikelenboom, and R. Veerhuis, "Astrocytic Aβ1-42 uptake is determined by Aβ-aggregation state and the presence of amyloid-associated proteins, " GLIA, vol. 58, no. 10, pp. 1235-1246, 2010.
78. A. Y. Lai and J. McLaurin, "Mechanisms of amyloid-β peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins, " International Journal of Alzheimers Disease, vol. 2011, Article ID 548380, 11 pages, 2011.
79. M. Sakono and T. Zako, "Amyloid oligomers: formation and toxicity of Aβ oligomers, " FEBS Journal, vol. 277, no. 6, pp. 1348-1358, 2010.
80. K. Tahara, H. Kim, J. Jin, J. A. Maxwell, L. Li, and K. Fukuchi, "Role of toll-like receptor signalling in Aβ uptake and clearance, " Brain, vol. 129, no. 11, pp. 3006-3019, 2006.
81. H. Fu, B. Liu, J. L. Frost, et al., "Complement componentC3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia, " GLIA, vol. 60, no. 6, pp. 993-1003, 2012.
82. C. N. Yang, Y. J. Shiao, F. S. Shie, et al., "Mechanismmediating oligomeric Aβ clearance by naive primary microglia, " Neurobiology of Disease, vol. 42, no. 3, pp. 221-230, 2011.
83. A. NSongo, T. Kanekiyo, and G. Bu, "LRP1 plays amajor role in the amyloid-β clearance in microglia, " Molecular Neurodegeneration, vol. 8, supplement 1, p. P33, 2013.
84. A. Griciuc, A. Serrano-Pozo, A. R. Parrado, et al., "Alzheimers disease risk gene cd33 inhibits microglial uptake of amyloid β, " Neuron, vol. 78, no. 4, pp. 631-643, 2013.
85. D. Doens and P. L. Fernandez, "Microglia receptors and their implications in the response to amyloid β for Alzheimers disease pathogenesis, " Journal of Neuroinflammation, vol. 11, p. 48, 2014.
86. E. Sandwall, P. OCallaghan, X. Zhang, U. Lindahl, L. Lannfelt, and J. Li, "Heparan sulfate mediates amyloid-beta internalization and cytotoxicity, " Glycobiology, vol. 20, no. 5, pp. 533-541, 2010.
87. B. V. Zlokovic, "The blood-brain barrier in health and chronic neurodegenerative disorders, " Neuron, vol. 57, no. 2, pp. 178-201, 2008.
88. T. Kanekiyo, J. Zhang, Q. Liu, C. Liu, L. Zhang, and G. Bu, "Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-β uptake, " The Journal of Neuroscience, vol. 31, no. 5, pp. 1644-1651, 2011.
89. D. M. Holtzman, K. R. Bales, T. Tenkova, et al., "Apolipoprotein E isof orm-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimers disease, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 6, pp. 2892-2897, 2000.
90. Q. Jiang, C. Y. D. Lee, S. Mandrekar, et al., "ApoE promotes the proteolytic degradation of Aβ, " Neuron, vol. 58, no. 5, pp. 681-693, 2008.
91. T. Kanekiyo, H. Xu, and G. Bu, "ApoE and Aβ in Alzheimers disease: accidental encounters or partners?" Neuron, vol. 81, no. 4, pp. 740-754, 2014.
92. P. O'Callaghan, F. Noborn, D. Sehlin, et al., "Apolipoprotein E increases cell association of amyloid-β 40 through heparan sulfate and LRP1 dependent pathways, " Amyloid, vol. 21, no. 2, pp. 76-87, 2014.
93. A. R. Simard, D. Soulet, G. Gowing, J. Julien, and S. Rivest, "Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimers disease, " Neuron, vol. 49, no. 4, pp. 489-502, 2006.
94. D. Frenkel, K. Wilkinson, L. Zhao, et al., "Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimers-like disease progression, " Nature Communications, vol. 4, article 2030, 2013.
95. M. Fiala, J. Lin, J. Ringman, et al., "Ineffective phagocytosis of amyloid-β by macrophages of Alzheimers disease patients, " Journal of Alzheimers Disease, vol. 7, no. 3, pp. 221-232, 2005.
96. L. Wang, M. Fuster, P. Sriramarao, and J. D. Esko, "Endothelial heparan sulfate deficiency impairs L-selectin-and chemokinemediated neutrophil trafficking during inflammatory responses, " Nature Immunology, vol. 6, no. 9, pp. 902-910, 2005.
97. C. Zarow, E. Barron, H. C. Chui, and L. S. Perlmutter, "Vascular basement membrane pathology and Alzheimers disease, " Annals of the New York Academy of Sciences, vol. 826, pp. 147-160, 1997.
98. D. Bonneh-Barkay and C. A. Wiley, "Brain extracellular matrix in neurodegeneration, " Brain Pathology, vol. 19, no. 4, pp. 573-585, 2009.
99. C. A. Hawkes, W. Hartig, J. Kacza, et al., "Perivascular drainage of solutes is impaired in the ageingmouse brain and in the presence of cerebral amyloid angiopathy, " Acta Neuropathologica, vol. 121, no. 4, pp. 431-443, 2011.
100. L. Bergamaschini, E. Rossi, C. Storini, et al., "Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces pl aques and β-amyloid accumulation in a mouse model of Alzheimer's disease, " Journal of Neuroscience, vol. 24, no. 17, pp. 4181-4186, 2004.
101. Z. Scholefield, E. A. Yates, G. Wayne, A. Amour, W. McDowell, and J. E. Turnbull, "Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimers β-secretase, " Journal of Cell Biology, vol. 163, no. 1, pp. 97-107, 2003.
102. D. H. Small, D. W. Klaver, and M. Beckman, "Regulation of proBACE1 by glycosaminoglycans, "NeurodegenerativeDiseases, vol. 5, no. 3-4, pp. 206-208, 2008.
103. R. Schworer, O. V. Zubkova, J. E. Turnbull, and P. C. Tyler, "Synthesis of a targeted library of heparan sulfate hexa-to dodecasaccharides as inhibitors of β-secretase: potential therapeutics for Alzheimers disease, " Chemistry A, vol. 19, no. 21, pp. 6817-6823, 2013.